LongGHJun 2026
Guardant Health
Guardant Health benefited from several company-specific catalysts during the quarter. These included FDA approval of an updated Guardant360 liquid-biopsy test, inclusion of…
GH
1 published idea on Guardant Health across 1 fund — 1 long and 0 short.
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Guardant Health: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Guardant Health benefited from several company-specific catalysts during the quarter. These included FDA approval of an updated Guardant360 liquid-biopsy test, inclusion of…